Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
Mabs|February 5, 2014
Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicityStefanie Derer, Pia Glorius, Martin Schlaeth, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2015
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor CellsStefanie Derer, Michael Cossham, Thies Rösner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2017
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized CellsAnnalina Tammen, Stefanie Derer, Ralf Schwanbeck, et al.
Haematologica|June 6, 2020
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapyKatja Klausz, Michael Cieker, Christian Kellner, et al.
Cancer Science|March 25, 2010
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cellsMartin Schlaeth, Sven Berger, Stefanie Derer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 2010
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cellsYvonne Guettinger, Karin Barbin, Matthias Peipp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2011
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killingStefan Lohse, Stefanie Derer, Thomas Beyer, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector FunctionsCarina Lynn Gehlert, Steffen Krohn, Dorothee Winterberg, et al.
British Journal of Haematology|July 21, 2005
Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16)Joerg Bruenke, Karin Barbin, Susanne Kunert, et al.
Cancers|July 14, 2023
Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9Chilam Chan, Marta Lustig, J H Marco Jansen, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
Mabs|February 5, 2014
Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicityStefanie Derer, Pia Glorius, Martin Schlaeth, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2015
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor CellsStefanie Derer, Michael Cossham, Thies Rösner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2017
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized CellsAnnalina Tammen, Stefanie Derer, Ralf Schwanbeck, et al.
Haematologica|June 6, 2020
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapyKatja Klausz, Michael Cieker, Christian Kellner, et al.
Cancer Science|March 25, 2010
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cellsMartin Schlaeth, Sven Berger, Stefanie Derer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 2010
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cellsYvonne Guettinger, Karin Barbin, Matthias Peipp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2011
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killingStefan Lohse, Stefanie Derer, Thomas Beyer, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector FunctionsCarina Lynn Gehlert, Steffen Krohn, Dorothee Winterberg, et al.
British Journal of Haematology|July 21, 2005
Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16)Joerg Bruenke, Karin Barbin, Susanne Kunert, et al.
Cancers|July 14, 2023
Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9Chilam Chan, Marta Lustig, J H Marco Jansen, et al.
Pageof 11